News Processa Pharmaceuticals, Inc.

Stocks

PCSA

US74275C4033

Biotechnology & Medical Research

Market Closed - Nasdaq 16:30:00 2026-10-30 EDT			5-day change	1st Jan Change
1.890 ^USD	0.00%		+4.42%	-34.38%

08-14	Processa Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
07-29	Processa Pharmaceuticals, Inc. announced that it has received $200 million in funding from a group of investors	CI

All News

Mentions Relevance

09-01	Processa Pharmaceuticals to Participate in Upcoming Investor Conferences	AQ
08-14	Processa Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
07-30	Processa Pharmaceuticals : Initial Statement of Beneficial Ownership (Form 3)	PU
07-29	Processa Pharmaceuticals, Inc. announced that it has received $200 million in funding from a group of investors	CI
07-29	Processa Pharmaceuticals, Inc. acquired Vidya Therapeutics, Inc. for approximately $320 million.	CI
07-29	Processa Pharmaceuticals, Inc. - M&A Call
07-29	Processa Pharmaceuticals, Inc. announced that it expects to receive $200 million in funding from a group of investors	CI
07-29	Processa buys Vidya Therapeutics, raises $200 million for drug trials	RE
07-29	Processa Pharmaceuticals, Inc. Announces Appointment of Sheila Gujrathi as Director	CI
07-29	PROCESSA PHARMACEUTICALS, INC. ANNOUNCES ACQUISITION OF VIDYA THERAPEUTICS, INC. AND APPROXIMATELY $200 MILLION CONCURRENT PRIVATE PLACEMENT TO ADVANCE BTK INHIBITOR, VT-7208, IN MULTIPLE DISEASE AREAS	AQ
07-27	Processa Pharmaceuticals, Inc. announced that it expects to receive $200 million in funding	CI
05-07	Processa Pharmaceuticals : Quarterly Report for Quarter Ending March 31, 2026 (Form 10-Q)	PU
05-07	Processa Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
04-30	Processa Pharmaceuticals, Inc. Announces Transition of Employment Status of Sian Bigora, Chief Development and Regulatory Officer, Effective May 1, 2026	CI
03-18	Processa Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
03-17	Processa Pharmaceuticals, Inc. Auditor Raises 'Going Concern' Doubt	CI
02-19	Processa Pharmaceuticals, Inc. Announces Expiration of Binding Term Sheet with Intact Therapeutics	CI
01-12	Processa Pharmaceuticals to Attend 44th Annual J.P. Morgan Healthcare Conference	AQ
01-05	Processa Pharmaceuticals, Inc. Completes Enrollment of 20th Patient for Formal Interim Analysis in Phase 2 NGC-Cap Breast Cancer Study	CI
01-05	Processa Pharmaceuticals Completes Enrollment of 20th Patient for Formal Interim Analysis in Phase 2 NGC-Cap Breast Cancer Study	AQ
12-17	Processa Pharmaceuticals gives update on phase 2 study of metastatic breast cancer	RE
12-17	Processa Pharmaceuticals Provides Clinical Update on Phase 2 Study in Metastatic Breast Cancer	AQ
12-17	Processa Pharmaceuticals, Inc. Provides Clinical Update on Phase 2 Study in Metastatic Breast Cancer	CI
12-15	Processa Pharmaceuticals to effect 1-for-25 reverse stock split	RE
11-06	Processa Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI